At the 2026 ASCO Genitourinary Cancers Symposium, researchers shared encouraging advances in advanced prostate cancer care, aligned with the theme “Patient-Centered Care: From Discovery to Delivery.” New data on combination therapies showed longer disease control, with a strong focus on preserving quality of life.
Below are some of the top findings from this global event.
A large phase 3 trial found that combining enzalutamide (Xtandi) with radium -223 (Xofigo) helped men with metastatic castration-resistant prostate cancer (mHSPC) that has spread to the bones live longer than taking enzalutamide alone. On average, men who received the combination therapy had nearly six extra months of survival. The treatment also delayed how long it took for the cancer to worsen on scans. These findings are significant because they support the combination as a new first-line option for this patient population.
A large clinical trial found that adding a targeted therapy (Lu-PSMA-617) to standard hormone therapy helped slow the growth of mHSPC compared with standard treatment alone. Men who received the added treatment generally had less pain and improved health-related quality of life. This data suggests doctors may have another option to treat mHSPC without significantly affecting how patients feel or function in their daily lives.
Combining abiraterone (Zytiga) with capivasertib (Truqap) helped delay cancer growth in men with mHSPC whose tumors have a PTEN gene loss. Men who received the combination went about 33 months before their cancer worsened on scans, compared with about 26 months for those who received abiraterone alone. Side effects were generally temporary and overall quality of life was largely maintained. These results are important because they point to a more personalized treatment option for patients with PTEN-deficient prostate cancer, potentially offering longer disease control.
Connect with other patients living with cancer and join the Outcomes4Me Community. Share your story, offer guidance, or simply read along.
Personalized support for real care decisions
Understand your diagnosis, explore clinical trials, and track symptoms--all in one place.
Get started
Compare treatments, prepare for appointments, and track side effects—all in the app
Built for your diagnosis, Outcomes4Me gives you the tools to make confident, informed decisions—right when you need them.
Continue in app
